Boston Scientific study shows benefits of Alair for bronchial thermoplasty

Boston Scientific has announced the findings of a new study showing the benefits offered by its Alair system in the delivery of bronchial thermoplasty.

The PAS2 study enrolled 284 patients at 27 research centres across the US and Canada, with all participants affected by asthma that was not well controlled by inhaled corticosteroids and long-acting beta-agonist therapy.

Marked clinical improvements were achieved by the Alair treatment recipients, which were sustained for two years after treatment ended. The percentage of study participants that had at least one severe asthma exacerbation, for example, decreased from 77.8 percent in the year prior to treatment to 50.4 percent in year one and 46.4 percent in year two.

Art Butcher, senior vice-president and president for endoscopy at Boston Scientific, said: "We are committed to working with the healthcare community to ensure that patients with severe asthma have access to this important treatment option."

Alair System is the first non-pharmacologic device-based treatment for severe, persistent asthma, delivering controlled thermal energy to the airway wall to reduce the amount of excess smooth muscle tissue in the airways.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.